It’s official. Primary care is out; oncology is the new therapeutic area of choice for Big Pharma desperate for new products. On October 6, Eli Lilly & Co. became the latest pharmaceutical company to jump on the cancer bandwagon, with its $6.5 billion acquisition of ImClone Systems Inc.[See Deal] "The combination of Lilly’s and ImClone’s current cancer franchises creates a true oncology powerhouse," said John Lechleiter, Lilly’s president and CEO in a conference call announcing the deal. The central question now is whether the Indianapolis-based pharmaceutical company can turn the buyout—the largest in its history--into a win for shareholders.
Much of Lilly’s justification for the acquisition hinges on ImClone’s interesting but early-stage oncology pipeline. The deal gives Lilly the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?